Council Workgroups

People With Lived/Living Experience of Substance Use Workgroup

Charge

To advise on ways to enhance and increase meaningful engagement of people who have lived or living experience with drug use in NIDA-funded research.

Image
Flyer cover
Download Flyer (PDF, 72KB)

Are you passionate about making sure the perspectives of people who use or have used drugs are incorporated into research? Do you want to help shape expectations for meaningfully engaging people with lived and living experience of substance use in research?

We are excited to share that the National Institute on Drug Abuse (NIDA) is launching a working group to the National Advisory Council on Drug Abuse (NACDA) made up of people with lived or living experience (PWLLE) with drug use. The primary purpose of the group will be to advise on ways to enhance and increase meaningful engagement of PWLLE with drug use in NIDA-funded research. Workgroup members will provide input and feedback to help NIDA co-create standards for engagement of PWLLE in research that will serve as a resource for researchers and PWLLE about NIDA’s expectations regarding engagement in research. 

NIDA is seeking workgroup members who identify as having current or former experience themselves with substance use or substance use disorder, or as a family member or caregiver of someone who does. The workgroup will meet for 1-2 hours approximately 3-4 times a year during 2025 and potentially into 2026. Workgroup meetings will be virtual to facilitate broad participation from around the U.S. Access to Zoom via computer, phone, or tablet will be necessary to participate. There will be current NACDA members as representatives on the workgroup. Workgroup members will be paid $200 per meeting as compensation for their time and there will be no requirements for work outside of meeting times. Workgroup meetings will not be public, but the names of workgroup members will be public information shared on NIDA’s website. Registered lobbyists are not eligible to serve on this workgroup.

If you are interested in participating in this opportunity, please send a brief personal statement in any format (written, audio, or video recorded) to PWLLEworkgroup@nida.nih.gov by January 10th, 2025. In your statement, you might include:

  • How your relevant lived or living expertise would be an asset to the workgroup. 
  • A brief description of any substance use-related research you have been involved in before in any capacity (researcher, advisor, or participant). Previous experience with research is not required. 
  • If you are comfortable, please share your geographic and demographic (age, race/ethnicity, gender) information so we can ensure we engage a diverse set of voices in the group.

Please reach out to PWLLEworkgroup@nida.nih.gov with any questions.

OMB Control Number: 0925-0766    Expiration Date: 09/2026 

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering, and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a current valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0766). Do not return the completed form to this address.


Division of Therapeutics and Medical Consequences Workgroup

Charge

To provide scientific input on the current and future research portfolio for NIDA’s Division of Therapeutics and Medical Consequences.

To provide input on the development of medications and devices to treat SUD and review concepts and recommend emerging pharmacotherapies, behavioral therapies and devices to treat SUD.

Members

Chair:
Kalpana Merchant, Ph.D.
Chief Scientific Officer
Vincere Biosciences

Lisa Gold, Ph.D.
Retired - Merck
Consultant

David McKinzie, Ph.D.
Professor of Pharmacology & Toxicology
Indiana University School of Medicine
Stark Neurosciences Research Institute

Chris Schmidt, Ph.D.
Retired - Pfizer